Form 4: Lucid Diagnostics Inc. President and COO, Shaun O'Neil, Reports Acquisition of 300,000 Shares of Common Stock

Shaun O'Neil, President and COO of Lucid Diagnostics Inc., reports acquiring 300,000 shares of common stock on February 20, 2025, as part of a restricted stock grant.

Summary

• On February 20, 2025, Shaun O'Neil, the President and COO of Lucid Diagnostics Inc., acquired 300,000 shares of common stock.
• The acquisition was a result of a restricted stock grant under the Issuer's 2018 Equity Plan.
• The restricted stock has a single vesting date of May 20, 2028, and is subject to forfeiture if the service period is not completed.
• Mr. O'Neil also beneficially owns 826,763 shares of Lucid common stock, which includes 6,763 shares distributed by PAVmed on February 15, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects an executive receiving a stock grant, indicating alignment with company performance and future growth. It's a routine filing, but the increased ownership can be seen as a positive sign.

Positives

• The acquisition of 300,000 shares by the President and COO demonstrates confidence in the company's future.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if O'Neil leaves the company before May 20, 2028.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The increased stock ownership of a key executive could positively influence investor confidence.

Key Dates

Keywords

Lucid Diagnostics, Shaun O'Neil, Form 4, Beneficial Ownership, Restricted Stock, Equity Plan, LUCD